Alendronate Sodium Tablet
Product Images NDC 68788-7130

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 68788-7130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (1203dd0c 809a 4409 B948 B5e816b8a63a 01)

Chemical structure of Alendronate sodium showing its molecular arrangement including amine, carbon, phosphate groups, and three water molecules as hydrate.*

FDA Label Image

2 (1203dd0c 809a 4409 B948 B5e816b8a63a 02)

A line graph depicting the cumulative incidence of hip fractures over 36 months in patients with baseline radiographic vertebral fractures. It compares two groups: Placebo and Alendronate Sodium. The y-axis shows cumulative incidence percentage, and the x-axis shows time in months, illustrating that the Alendronate Sodium group had a lower incidence than the placebo group throughout the study.*

FDA Label Image

3 (1203dd0c 809a 4409 B948 B5e816b8a63a 03)

A bar chart depicting osteoporosis treatment studies in postmenopausal women, showing percent increase in bone mineral density (BMD) at three years with Alendronate Sodium 10 mg/day. The chart compares BMD percent increase relative to placebo between U.S. and multinational populations for three bone regions: lumbar spine, femoral neck, and trochanter, with error bars indicating standard error.*

FDA Label Image

4 (1203dd0c 809a 4409 B948 B5e816b8a63a 04)

Line charts depicting osteoporosis treatment studies in postmenopausal women, showing the time course effect of Alendronate Sodium 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline over 36 months. Separate graphs illustrate results from a US study and a multinational study, with BMD percentage change plotted against time in months.*

FDA Label Image

5 (1203dd0c 809a 4409 B948 B5e816b8a63a 05)

A figure with two bar charts titled 'Osteoporosis Prevention Studies in Postmenopausal Women.' The left chart shows change in bone mineral density (BMD) from baseline over a 2-year study across lumbar spine, femoral neck, trochanter, and total body for Alendronate Sodium 5mg/day versus placebo. The right chart shows similar BMD changes over a 3-year study for the same groups and body regions.*

FDA Label Image

6 (1203dd0c 809a 4409 B948 B5e816b8a63a 06)

A bar graph showing the increase in bone mineral density (BMD) percentage at one year with Alendronate Sodium 5 mg/day in glucocorticoid-treated patients. The graph compares mean percentage BMD increase relative to placebo at three sites: Lumbar Spine, Femoral Neck, and Trochanter, for U.S. and Multinational patient groups, including error bars indicating standard error.*

FDA Label Image

7 (1203dd0c 809a 4409 B948 B5e816b8a63a 07)

A line graph depicting the effect on serum alkaline phosphatase levels over six months in patients with Paget's Disease of Bone. It compares alendronate sodium 40 mg/day (multinational and U.S. studies), etidronate 400 mg/day, and placebo, showing percent change from baseline over time with error bars and sample sizes (N) noted.*

FDA Label Image

Alendronate Sodium Tablets, Usp 70mg (1203dd0c 809a 4409 B948 B5e816b8a63a 09)

Alendronate Sodium Tablets, USP 70 mg tablet label for oral use, generic for Fosamax, manufactured by Cipla USA, Inc., and labeled by Preferred Pharmaceuticals Inc. The label highlights the dosage strength of 70 mg and includes storage instructions and a caution against transferring the drug to others. Directions to take the tablet as directed are presented bilingually in English and Spanish.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.